Can a new injection shrink nasal polyps and restore easy breathing?
NCT ID NCT07755371
First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time
Summary
This trial is testing an experimental drug called AK139, given as an injection, in people with chronic sinusitis and nasal polyps—growths in the nose that block airflow. The study compares AK139 against a placebo, with all participants also using a standard steroid nasal spray. The goal is to see if AK139 can reduce polyp size and ease nasal congestion better than the spray alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AK139, an experimental biologic given as an injection
- What this could lead to
- If effective, AK139 could offer a new non-surgical option to reduce nasal polyps and improve breathing for people with chronic sinusitis.
- What could go wrong
- This is an early phase II study with a small number of participants, so results may not hold up in larger trials. As a biologic injection, it may also carry side effects like allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP) are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eye & ENT Hospital of Fudan University
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a Pre-Surgery drug boost nasal polyp treatment?
- New study tests tezepelumab for chronic sinusitis sufferers
- 88% of patients with asthma and nasal polyps achieve dual remission on dupilumab
- Scientists probe the root cause of smell loss in chronic sinusitis
- Could a simple mucus test transform nasal polyp treatment?
- New drug BBT002 aims to ease sinus and asthma symptoms